Breast cancer and spironolactone: an observational postmarketing study.


Journal

European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 26 04 2019
accepted: 09 08 2019
pubmed: 17 8 2019
medline: 10 3 2020
entrez: 17 8 2019
Statut: ppublish

Résumé

Recent studies have discussed the risk of breast cancer with antihypertensive drugs. For spironolactone, data are conflicting. The present paper investigates this potential signal in VigiBase In VigiBase During the study period, 125 ICSRs reported spironolactone exposure and breast malignant cancer in women ≥ 50 years. We failed to find a positive association between spironolactone exposure and breast cancer in comparison with exposure to other drugs (aROR = 0.63 95% CI [0.52-0.75]) or pseudo aldosterone antagonists (amiloride, triamterene) (0.56 [0.44-0.72]). Similar trends were found after exclusion of drug competitors and/or reports from health professionals. This study did not find evidence for breast cancer associated with spironolactone.

Identifiants

pubmed: 31418056
doi: 10.1007/s00228-019-02740-y
pii: 10.1007/s00228-019-02740-y
doi:

Substances chimiques

Diuretics 0
Spironolactone 27O7W4T232

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1593-1598

Références

Largent JA, McEligot AJ, Ziogas A, Reid C, Hess J, Leighton N, Peel D, Anton-Culver H (2006) Hypertension, diuretics and breast cancer risk. J Hum Hypertens 20:727–732
doi: 10.1038/sj.jhh.1002075
Gómez-Acebo I, Dierssen-Sotos T, Palazuelos C, Pérez-Gómez B, Lope V, Tusquets I, Alonso MH, Moreno V, Amiano P, Molina de la Torre AJ, Barricarte A, Tardon A, Camacho A, Peiro-Perez R, Marcos-Gragera R, Muñoz M, Michelena-Echeveste MJ, Ortega Valin L, Guevara M, Castaño-Vinyals G, Aragonés N, Kogevinas M, Pollán M, Llorca J, Gómez-Acebo I, Dierssen-Sotos T, Palazuelos C, Pérez-Gómez B, Lope V, Tusquets I, Alonso MH, Moreno V, Amiano P, de la Torre AJ M, Barricarte A, Tardon A, Camacho A, Peiro-Perez R, Marcos-Gragera R, Muñoz M, Michelena-Echeveste MJ, Ortega Valin L, Guevara M, Castaño-Vinyals G, Aragonés N, Kogevinas M, Pollán M, Llorca J (2016) The use of antihypertensive medication and the risk of breast cancer in a case-control study in a Spanish population: the MCC-Spain study. PLoS One 11:e0159672
doi: 10.1371/journal.pone.0159672
Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 98:1504–1513
doi: 10.1002/cncr.11663
Zhao Y, Wang Q, Zhao X, Meng H, Yu J (2018) Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: evidence from observational studies. Clin Exp Hypertens 40:22–27
doi: 10.1080/10641963.2017.1288736
Jackson EK (2018) Drugs affecting renal excretory function. In: Brunton LL, Hilal-Dandan R, Knollmann BJ (eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 13th edn. New York, Mc Graw Hill, pp 445–470
Miyatake A, Noma K, Nakao K, Morimoto Y, Yamamura Y (1978) Increased serum oestrone and oestradiol following spironolactone administration in hypertensive men. Clin Endocrinol 9:523–533
doi: 10.1111/j.1365-2265.1978.tb01510.x
Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M (2013) Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol 37:870–875
doi: 10.1016/j.canep.2013.10.004
Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L (2012) Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ 345:e4447
doi: 10.1136/bmj.e4447
Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM (2017) Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 83:653–663
doi: 10.1111/bcp.13152
Bate A, Lindquist M, Edwards IR (2008) The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 22:127–140
doi: 10.1111/j.1472-8206.2007.00552.x
Bergvall T, Norén GN, Lindquist M (2014) VigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf 37:65–77
doi: 10.1007/s40264-013-0131-x
Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis and management. Lancet 356:1255–1259
doi: 10.1016/S0140-6736(00)02799-9
Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905–908
doi: 10.1111/j.1365-2125.2011.04037.x
Faillie JL (2019) Case-non case studies: principles, methods, bias and interpretation. Therapie 74:225–232
doi: 10.1016/j.therap.2019.01.006
Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2:133–140
doi: 10.1016/S1470-2045(00)00254-0
Fentiman IS (2016) Male breast cancer is not congruent with the female disease. Crit Rev Oncol Hematol 101:119–124
doi: 10.1016/j.critrevonc.2016.02.017
Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36:237–249
doi: 10.1053/j.seminoncol.2009.03.001
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5(Suppl 1):S2–S8
pubmed: 23819024 pmcid: 3695538
(1975) Editorial: reserpine and breast cancer. Can Med Assoc J 112:129
Grossman E, Messerli FH, Goldbourt U (2001) Antihypertensive therapy and the risk of malignancies. Eur Heart J 22:1343–1352
doi: 10.1053/euhj.2001.2729
Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salamé G, Fourrier-Reglat A, Haramburu F, Bégaud B, Moore N, Association Française des Centres Régionaux de Pharmacovigilance (CRPV) (2012) Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf 35:855–864
doi: 10.1007/BF03261981
Bezin J, Bosco-Levy P, Pariente A (2017) False-positive results in pharmacoepidemiology and pharmacovigilance. Therapie 72:415–420
doi: 10.1016/j.therap.2016.09.020
Vial T (2016) French pharmacovigilance: missions, organization and perspectives. Therapie 71:143–150
doi: 10.1016/j.therap.2016.02.029
Loube SD, Quirk RA (1975) Breast cancer associated with administration of spironolactone. Lancet 1(7922):1428–1429
doi: 10.1016/S0140-6736(75)92645-8
Shaw JC (1991) Spironolactone in dermatologic therapy. J Am Acad Dermatol 24:236–243
doi: 10.1016/0190-9622(91)70034-Y
Cunliffe WJ (1992) Spironolactone in dermatology. J Am Acad Dermatol 26:137–138
doi: 10.1016/S0190-9622(08)80535-X
Montastruc JL, Benevent J, Montastruc F, Bagheri H, Despas F, Lapeyre-Mestre M, Sommet A (2019) What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie 74:169–174
doi: 10.1016/j.therap.2018.08.001
Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, Platt RW, Bouganim N, Azoulay L (2018) Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 363:k4880. https://doi.org/10.1136/bmj.k4880
doi: 10.1136/bmj.k4880 pubmed: 30518618 pmcid: 6278586
Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385–396
doi: 10.2165/00002018-200629050-00003

Auteurs

Pierre Sabatier (P)

Service de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France.

Jacques Amar (J)

Service Hypertension Artérielle et Thérapeutique, Centre Hospitalier Universitaire, UMR INSERM 1027, Toulouse, France.

François Montastruc (F)

Service de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France.

Vanessa Rousseau (V)

Service de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France.

Leila Chebane (L)

Service de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France.

Béatrice Bouhanick (B)

Service Hypertension Artérielle et Thérapeutique, Centre Hospitalier Universitaire, UMR INSERM 1027, Toulouse, France.

Jean-Louis Montastruc (JL)

Service de Pharmacologie Médicale et Clinique, Centre de PharmacoVigilance, de Pharmaco-épidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, UMR INSERM 1027, Faculté de Médecine - Centre Hospitalier Universitaire, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH